The TRIUMPH trial evaluates eculizumab's efficacy in reducing transfusion requirements and stabilizing hemoglobin levels in PNH patients, a condition with significant unmet medical needs. The successful outcome of this trial could reinforce eculizumab's position in the market, potentially expanding its label indications and increasing market share in the rare disease segment. Given the high cost of eculizumab and the limited competition in the PNH space, positive results may lead to increased revenue streams for the sponsor, Jonsson Comprehensive Cancer Center, and its collaborators. Stakeholders should consider the implications of trial outcomes on pricing strategies and market access, particularly in regions with stringent reimbursement frameworks.